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Resumen
Objetivo: Remdesivir no ha mostrado beneficio en supervivencia para 
pacientes con COVID-19 grave. Sin embargo, el análisis por subgrupos del 
estudio ACTT-1 mostró aparente reducción de mortalidad en pacientes que 
requerían oxígeno –no de alto flujo–. La difusión de resultados del estudio 
SOLIDARITY se acompañó de un metaanálisis que combinó resultados de 
mortalidad por subgrupos de los ensayos clínicos aleatorizados. El objetivo 
del presente estudio es analizar metodológicamente la fiabilidad y aplica-
bilidad clínica de los hallazgos por subgrupos sobre el efecto de remdesivir 
en mortalidad en pacientes con COVID-19. 
Método: Se usó una herramienta validada para valorar los hallazgos 
de los análisis por subgrupos en ensayos clínicos aleatorizados, incluido 
el metaanálisis anexo al estudio SOLIDARITY. La herramienta utilizada está 
estructurada en cuestiones preliminares para descartar análisis por subgru-
pos sin condiciones mínimas relevantes, y un cuestionario específico. Este 
último considera determinados criterios: asociación estadística, incluyendo 
p de interacción, preespecificación de subgrupos, tamaño muestral, número 
de factores valorados y resultado global del estudio; plausibilidad bioló-
gica de las diferencias observadas; y consistencia entre resultados de estu-
dios similares. Se asignó una puntuación a cada criterio y la herramienta 
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Introduction
The World Health Organization has recently published the interim results 
of the SOLIDARITY randomized clinical trial (RTC)1. In this study, remdesivir 
once again failed to demonstrate a clinical benefit in terms of 28-day mor-
tality reduction in patients diagnosed with severe COVID-19. Nonetheless, 
on this occasion 28-day mortality was the main endpoint in the study and 
the number of patients recruited was greater than in previous studies. This 
null effect on mortality had already been suggested by previous studies with 
lower statistical power, such as the ACTT-12 and the SIMPLE3 trials, and the 
paper by Wang et al.4.
In contrast to this, a subgroup analysis of severe COVID-19 patients 
with non-high-flow (NHF) oxygen support in the ACTT-1 trial suggested 
a potential mortality reduction in these patients treated with remdesivir2. 
It seems reasonable to think that an antiretroviral could be effective in 
controlling the disease in the early stages, before the consequences of 
an uncontrolled immune response render any kind of viral suppression 
almost useless. This beneficial effect of remdesivir on the course of the 
disease, then, seems more likely in patients whose respiratory distress 
is not yet severe enough to require ventilatory support. However, this 
effect has not been shown to be life-saving in any of the 7,600 subjects 
randomized into the four clinical trials performed to date with remdesi-
vir1-4. It should not be forgotten that the main goal of any anti-COVID-19 
treatment is to reduce mortality, which is something only dexamethasone 
has achieved5.
The different RCTs conducted on the use of remdesivir in the treatment 
of severe COVID-19 have not succeeded in showing any benefit in terms 
of overall mortality, and have cast many doubts over the benefits that rem-
desivir could provide to the subgroup of hospitalized patients with NHF 
oxygen support1-4. It is therefore extremely interesting to investigate the 
subgroups in the SOLIDARITY trial in search for answers. The published 
interim results of the SOLIDARITY trial include a meta-analysis that evalua-
tes the outcomes of the subgroup analyses contained in the four RCTs on 
severe COVID-19 published. The total population of these studies was 
subdivided into high and low-risk patients (those not receiving ventilatory 
support), including the subjects with high flow and NHF oxygen support 
in the SOLIDARITY trial. An analysis of the results of this meta-analysis 
could provide useful information on the mortality reduction achieved by 
remdesivir according to the patients’ risk profiles, leading to an increased 
understanding of the effect of remdesivir on the mortality of patients with 
NHF oxygen therapy. 
It should be noted that application of a subgroup analysis requires 
the acceptance of a high level of uncertainty6, resulting from the need to 
make a series of additional measurements and redistribute patients into 
different groups. An unbalanced distribution of benefit-related factors 
increases the potential α error, by the possibility of detecting apparent 
differences that do not really exist. Moreover, dividing the study popula-
tion into subgroups may make it even less likely to detect the differences 
between subgroups (increased β error). There is actually no consensus 
as to what should be the right consideration to subgroup analysis7, which 
in all cases requires a systematic and methodic evaluation before a 
clinical decision can be made. Taking into consideration the above, the 
purpose of this study was to conduct a methodological interpretation of 
the effect of remdesivir on 28-day mortality in the patients with severe 
COVID-19 presented in the subgroup meta-analysis of RCTs according 
to their risk profile.
Methods
The well-organized and systematic interpretation of the subgroup 
meta-analysis of the SOLIDARITY trial was possible thanks to the use 
of a validated tool (checklist) to determine the applicability of the sub-
group analysis8. The structure of the checklist presented two parts: a 
first part with preliminary questions aimed at ruling out the subgroup 
analyses that did not meet a series of minimum requirements, and a 
second part that consisted of a questionnaire. A negative answer to any 
of the preliminary questions discarded the applicability of the subgroup 
analysis without the need of confirmation by the checklist. The checklist 
considered a series of criteria for interpreting the subgroup analysis: 
statistical association, which included the interaction p value [p(i)], which 
indicates the probability that differences between subgroups may be 
at random, subgroup pre-specification, sample size, number of factors 
analyzed and overall result of the study; biological plausibility of the 
differences between subgroups; and consistency between the results of 
similar studies. When an article did not provide a p(i) value, it was 
estimated using a subgroup calculator9. Answers to the questions related 
to statistical association, biological plausibility, and consistency were 
assigned one of the following scores: probable (+3 points), possible 
(+2 points), doubtful (0 points) and null (–3 points). The overall cumulative 
value was associated with a recommendation about the applicability of 
the findings for a subgroup to the adoption of clinical decisions. A null 
statistical association or consistency score resulted in a direct exclusion 
of any findings. Higher scores were related to a greater reliability of the 
findings of a specific subgroup analysis: the probable score (9-7 points) 
meant that the findings of the subgroup analysis could be applicable 
until a confirmatory RCT was developed; a possible score (5-6 points) 
meant that the findings could be applied with caution in cases of low 
tolerance, difficulty of use or high cost of therapeutic alternatives; the 
doubtful score (3-4 points) indicated that applicability was rejected, with 
a few exceptions; and finally, the null score (<3 points) indicated abso-
lute inapplicability of the subgroup findings.
Subsequently, an estimation was made of the benefit that could be obtai-
ned by the low-risk subgroup of meta-analysis that accompanies the SOLIDA-
RITY trial1, as that cohort included the subgroup of patients in the ACTT-1 trial 
with NHF oxygen therapy, for whom a potential reduction in mortality has 
been suggested2. The magnitude of the benefit was estimated by calculating 
the number needed to treat (NNT) to prevent one additional event and the 
relative risk reduction (RRR).
relacionó el sumatorio global con una recomendación sobre la aplicabili-
dad de los resultados de los subgrupos en la toma de decisiones clínicas. 
Resultados: Las cuestiones preliminares tuvieron respuestas positivas, 
aplicándose el cuestionario. La asociación estadística obtuvo valoración 
“nula” (–3 puntos), con p de interacción dudosa (p = 0,0650) y resultado 
de mortalidad no significativo en población global, restando fiabilidad al 
análisis de subgrupos. La plausibilidad biológica fue considerada “proba-
ble” (+3 puntos), ya que el antiviral pudiera tener mayor efecto antes del 
proceso inflamatorio y empeoramiento clínico. La consistencia se valoró 
“posible” (+2 puntos) por compatibilidad de resultados del estudio ACTT-1 
y SOLIDARITY. La recomendación de aplicación del análisis por subgrupos 
según el riesgo de los pacientes fue “nula”. 
Conclusiones: Esta interpretación estructurada de análisis por subgrupos 
sugiere que la hipótesis de que remdesivir podría reducir la mortalidad en 
pacientes con COVID-19 grave que precisan oxígeno –no de alto flujo– 
presenta demasiada incertidumbre, y es probable que sea un hallazgo 
casual. Por tanto, es imprescindible la realización de un ensayo clínico 
aleatorizado sobre mortalidad en pacientes con oxígeno –no de alto flujo–.
Results: Preliminary questions had positive answers, so checklist was 
applied. Statistical association obtained “null” assessment (–3 points), 
including a “doubtful” p of interaction (p = 0.0650) among subgroups 
and mortality reached no statistical significance for global population. 
These findings reduced the reliability of subset analysis. Biological plausi-
bility was considered “probable” (+3 points) because antiviral could have 
a greater effect before the inflammatory process and clinical worsening. 
Consistency between results of similar studies was evaluated as “possible” 
(+2 points) analysis for compatibility of ACTT-1 and SOLIDARITY study 
results. The recommendation about application of subset analysis results 
according to the risk of patients was “null”. 
Conclusions: This structured interpretation of subgroup analysis sugges-
ted too much uncertainty in hypothesis about remdesivir could reduce 
mortality in patients with severe COVID-19 who required non-high-flow 
oxygen. It was probably a random finding. Therefore, a randomized cli-
nical trial about effect of remdesivir in mortality in patients with COVID-19 
and non-high-flow oxygen is essential.
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Results
All the preliminary questions of the tool were answered in the affirma-
tive, which meant that the questionnaire could be applied. The subgroup 
of patients without ventilatory support in the meta-analysis accompan-
ying the SOLIDARITY study exhibited a ratio of death rates (RR) of 0.8 
[95% CI (0.63-1.01)], while the subgroup of high-risk patients obtained an 
RR of 1.16 [95% CI (0.85-1.60)]. With regard to statistical association, it was 
applied to the result of the meta-analysis in patients without ventilatory sup-
port or NHF oxygen therapy as opposed to the rest, a p(i) value of 0.0650 
was estimated between the subgroups, using RR values and a 95% confi-
dence interval. A p(i) value between 0.05 and 0.1 was considered accep-
table for the subgroup analysis as dividing the samples into the different 
subgroups reduced statistical power8,10. Thus, this p(i) value was assigned 
a “doubtful” score. The meta-analysis recreated the group of patients with 
NHF oxygen therapy and, even if the SOLIDARITY study did not include a 
pre-specification for this group, the subgroup analysis was developed accor-
ding to the patients’ risk profile given the apparent mortality benefit found by 
the ACTT-1 trial2. For this reason, a “probable” reliability score was assigned 
according to the pre-specification. As the sample size was much greater 
than 100 patients in both subgroups, a “probable” score was assigned to 
this criterion. About the number of factors analyzed is concerned, the same 
factors examined in the ACTT-1 trial were considered2, as the latter gave 
rise to the subgroup analysis that followed the meta-analysis. Moreover, the 
meta-analysis cannot evaluate the pre-specified factors as it only examines 
the factors considered in its constituent RCTs. The ACTT-1 trial analyzed 
7 factors (< 10) with a “probable” score2. Mortality did not reach statistical 
significance for the general population of the meta-analysis of the four trials 
(RR 0.91; 95% CI 0.79-1.05), which was indicative of an overall negative 
result. Although the result could have been positive in a specific subgroup, 
this possibility did not materialize as statistical significance was rot reached 
even in the subgroup of patients without ventilatory support/high-flow oxygen 
therapy (RR 0.80; 95% CI 0.63-1.01). As a result of this, statistical associa-
tion was given a “null” score as the assumption underlying this criterion (a 
negative outcome for the general population but a statistically significant 
difference for one of the subgroups) did not hold true. 
The biological plausibility of the subgroup analysis was given a “pro-
bable” score as there is a possibility that remdesivir may have a greater 
effect before the full inflammatory process responsible for clinical worsening 
gets underway, i.e. in patients still at the initial stages of the disease such 
as those in the low-risk group of the meta-analysis, among them the ones 
NHF oxygen therapy. Consistency was rated as “possible” as the differen-
tial interaction analysis in the ACTT-1 trial2, was not incompatible with the 
results of the SOLIDARITY trial which pointed in the same direction even if 
no statistical interaction was found. Although the other two studies in the 
meta-analysis, Wang et al. and SIMPLE3,4 did not show any consistency, 
their low statistical power means that they cannot by themselves reject a 
potential mortality benefit.
An examination of the findings above in the light of the criteria included 
in the validated tool8, indicates that recommending application of the sub-
group analysis to clinical decision-making according to the patients’ risk pro-
file was “null”, by direct discarding caused by unreliable statistical associa-
tion. Table 1 summarizes the interpretation of the subgroup analysis based 
on the patient’s clinical status included in the meta-analysis accompanying 
the SOLIDARITY trial.
Should a significant clinical benefit be eventually confirmed for remdesi-
vir, which is something that the meta-analysis has not been able to show, 
mortality in non-intubated patients/NHF oxygen therapy could decrease 
from 8.6% to 7.0%. This would entail an absolute risk reduction of 1.6% and 
hypothetically prevent one additional death in every 62 patients treated 
with remdesivir (NNT). Overall, in relative terms, it would be possible to 
prevent one in every five deaths in this patient population (1.6% over 8.6%, 
an 18.6% RRR).
Discussion
Considering that the final result of the validated tool about applicabi-
lity of the subgroup analysis was “null” in terms of mortality reduction in 
hospitalized COVID-19 patients with NHF oxygen therapy receiving rem-
desivir, the apparent mortality difference between the subgroups could 
be considered random. This means that mortality should not be assigned 
–for the time being– a value other than that found in the overall results 
of the meta-analysis accompanying the SOLIDARITY trial, RR = 0.91 
(95% CI 0.79-1.05). Nonetheless, the “null” reliability of this subgroup 
analysis, based on precarious data, does not exclude the hypothesis 
of a greater clinical benefit for the subgroup of patients requiring NHF 
oxygen support. 
The meta-analysis accompanying the SOLIDARITY trial presented a 
significant limitation1: the subgroups studied in the four RCTs analyzed 
were defined in an inconsistent manner1-4. It was not possible to develop 
an  individualized analysis of the NHF oxygen therapy subgroup, which 
 obtained an apparently significant benefit from remdesivir in the ACTT-1 
trial2, so the authors had to be limited to grouping patients with venti-
lation and patients without it. Patients with high-flow oxygen therapy or 
non-invasive ventilatory support in the ACTT-1 trial who were observed not 
to benefit from the treatment were incorporated to the group of patients on 
ventilatory support, which favored the appearance of differences between 
the low and high-risk subgroups in the meta-analysis accompanying the 
SOLIDARITY trial1. Furthermore, the subgroup made up of a combination 
of patients with and without high-flow oxygen therapy in the SOLIDARITY 
trial [RR 0.85 (0.66-1.09)] was included in the subgroup receiving no ven-
tilatory support. In addition, the magnitude of the benefit obtained by the 
low-risk subgroup of the SOLIDARITY trial1 suggests a doubtful mortality 
benefit in non-intubated patients. If this benefit existed, it could be much 
smaller than the one allegedly found in the subgroup of patients with NHF 
oxygen therapy in the ACTT-1 trial2.
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The present study is meant to contribute to contextualizing the results of 
the ACTT-1 trial2, where the subgroup of patients with NHF oxygen therapy 
obtained p(i) < 0.05. Although the analysis does not seem consistent with 
previous RCTs, the scenario is biologically plausible3,4. Instead of falling 
into the typical error associated with subgroup analysis evaluations whe-
reby conclusions are based on whether 95% CIs cross the neutral value or 
not9,11,12, a systematic interpretation was made of the most relevant results 
(RCT subgroup meta-analysis) relative to the effect of remdesivir on hospi-
talized COVID-19 patients according to their risk profile and clinical status. 
The current situation caused by the COVID-19 pandemic constitutes an 
unprecedented challenge for healthcare providers, among them hospital 
pharmacists13. The lack of effective therapeutic alternatives means that the 
use of remdesivir may be acceptable in patients with NHF oxygen therapy, 
even without any certainty that the antiviral can save their lives, and with 
the possibility that the intervention may just be anticipating the recovery of 
patients who would recover anyway. The available evidence does not sup-
port the conclusion that remdesivir does actually contribute to a reduction in 
mortality from COVID-19, which is the main goal of treatment, at least in the 
short term. This should result in the development of well-designed RCTs to 
investigate alternative treatments, regimens or usages that are really capa-
ble of saving patients’ lives. In that regard, it is essential to select 28-day 
mortality as the main outcome, rather than other variables such as relative 
recovery, which do not contribute to a better understanding of the disease 
or to making real solutions available. 
Finally, the mortality reduction observed in patients with NHF oxygen 
therapy is likely to be no more than an random finding. Even if the benefit 
was real, the results of the meta-analysis under study indicate that it is more 
modest than suggested by the isolated finding obtained in the ACTT-1 trial. 
A systematic analysis using the 28-day mortality endpoint discarded the 
applicability of remdesivir to any of the subgroups studied. Before prematu-
rely embracing the use of remdesivir in patients with NHF oxygen support 
during the current COVID-19 pandemic, it would be necessary to at least 
conduct an RCT to study the mortality of these patients so that the adminis-
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Contribution to the scientific literature
This is the first methodological assessment of the reliability of sub-
group analysis to determine the effect of remdesivir on mortality.
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